Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Complement C1”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 55 records · Page 3Linked to original sources
PubMed1981

Antibody-independent binding of the first component of complement (C1) and its subcomponent C1q to the S and R forms of Salmonella minnesota.

Strong bactericidal effects of normal guinea pig and human sera against the Salmonella minnesota S form and an R form (Re) depend on Ca2+, complement component C4, and subcomponent C1q of complement component C1. Therefore, the interaction of C1 and C1q with these forms was investigated. The bacteria directly bound subcomponent C1q, as demonstrated by fixation and transfer tests and by fluorescent methods. Binding of macromolecular C1 was shown by fixation and transfer tests and by C4 consumption. C1 fixation and transfer tests provide evidence that C1 and C1q were bound more tightly to the Re form than to the S form. At physiological ionic strength, all cell-bound molecules were released from the S form, whereas at least 60% remained on the cell surface of the Re form. The Re form showed another binding behavior for C1: preincubation of bacteria with purified C1q totally prevented C1 uptake by the S form, compared to only 10% inhibition of the uptake by the Re form. Therefore, we conclude that macromolecular C1 is bound differently by the S form than by the Re form. The analysis of five other core-deficient mutants of S. minnesota (Ra, Rb, Rc, Rd1, and Rd2) revealed that the difference could be explained by a deficiency of the O-specific polysaccharide. In contrast, all the C1q bound to Ra, Rb, and Rc mutants was detectable by the transfer test. Therefore, we postulate that binding of macromolecular C1 to these mutants must be due to an additional C1 subcomponent besides C1q.

Animals↗
PubMed1993

The phylogeny and evolution of the first component of complement, C1.

Extensive study of the phylogeny and evolution of the complement system has always been hampered by the difficulties involved in functional assays. These tests rely on the compatibility of the components from different species. Whereas all mammalian species appear to have almost identical classical, alternate and lytic pathways, non-mammalian vertebrates show minor differences. The source of the immunoglobulin molecule used to demonstrate classical pathway activation has also been shown to be crucial. The use of antibodies directed against complement components has been beneficial in the study of relationships, but cross-reactivity with non-complement proteins limited their use. The isolation and purification of complement components and the biochemical characterisation including amino acid analysis and peptide sequencing resulted in an enormous increase in our knowledge of the evolution of the complement system. Amino acid sequence analysis together with gene cloning of all human complement components finally revealed a number of sofar unknown features concerning the domain structure of the components and the relation of certain motifs and repeats to other proteins. The use of cDNA probes in Southern blot analysis of chromosomal DNA from various species enabled an extension of our scope of the phylogeny of complement. In this article we summarized the data on the phylogeny and evolution of the first component of complement and the associated molecules. We provide evidence for the conservation of the classical pathway and C1q in particular which appears to predate the divergence of the cartilaginous fish from the higher vertebrates. The possibility that the classical pathway could predate the alternate pathway is discussed.

Amino Acid Sequence↗
PubMed1994

Factor J, a human inhibitor of complement C1, is a cationic, highly glycosylated protein.

Factor J (FJ) is a new inhibitor of the complement system. This work supports the fact that FJ is a cationic molecule (pI > or = 9.6 in native conditions, or pI = 8.1 in denaturing conditions) with a high sugar content (40%) that is able to interact with different lectins, suggesting a complex glycosylation. SDS impaired FJ migration in polyacrylamide gel electrophoresis. In Triton-acid-urea-polyacrylamide gel electrophoresis FJ migrated as a complex, dispersed molecule. In contrast, FJ after Smith degradation (dFJ) gave a single, smeared band of M(r) = 23.4 kDa in reducing SDS-PAGE. dFJ retained only 60% of the initial inhibitory activity of intact FJ. When digestions with different proteinases were performed, no modification of activity was observed. After beta-glucuronidase digestion, FJ lost 80% of its initial activity. Consequently, glycosylation plays an important role in the inhibitory activity of FJ.

Carbohydrate Sequence↗
PubMed1987

Subunit interactions in the first component of complement, C1.

Interactions between C1q and other subunits of C1 were analyzed by sucrose gradient ultracentrifugation. A zone of dilute, radioiodine labelled C1q was sedimented through uniform concentrations of either C1r2C1s2, C1r2, C1r2 or C1s(2). The dissociation constants were found to be 3 x 10(-9) M and 6 x 10(-9) M for C1r2C1s2 and C1r2 binding respectively. Hill coefficients of 1 indicated no cooperativity in these bindings. Positive cooperativity was found in binding of C1s to C1q. Dissociation constants of 2 x 10(-6) M and 5 x 10(-8) M were obtained form computer modelling of a two step binding mechanism. No interaction was detected between C1q and activated C1r2. The data indicate that most of the interactions between C1q and C1r2C1s2 originates from a strong binding to the C1r2 moiety of the zymogen complex. This interaction is lost upon activation of C1r2.

Binding Sites↗
PubMed1996

Inhibition of the hemolytic activity of the first component of complement C1 by an Escherichia coli C1q binding protein.

Molecular mimicry is a well established mechanism via which bacteria protect themselves from complement-mediated killing. We have previously demonstrated that a number of human cells express receptors for C1q (C1qR) and that the soluble form of this receptor inhibits activation of the classical pathway of complement. We now investigated whether Escherichia coli possesses a C1qR-like protein that protects these bacteria from complement-mediated injury. By FACS analysis it was shown that approximately 60% of the bacteria bound C1q directly in the absence of Abs. With ELISA we confirmed that the bacterial cell envelope was able to bind C1q in a dose-dependent fashion. We isolated a cell envelope associated C1q binding protein (C1qBP) by C1q affinity chromatography, then by anion exchange chromatography and gel filtration chromatography. On SDS-PAGE, the m.w. of C1qBP appeared to be 57 kDa and 51 kDa under reducing and nonreducing conditions, respectively. It was demonstrated that C1qBP specifically binds C1q and inhibits the hemolytic activity of C1q in both a dose- and time-dependent fashion. The binding of C1qBP to C1q is inhibited by C1q itself and also by the collagen-like stalks and the globular heads of C1q. In this respect, bacterial C1qBP is different from human C1qR because the binding of C1q to C1qR is only inhibited by the collagen-like stalks of C1q and not by the globular heads of C1q. C1qBP, when bound to C1q, prevents the assembly with C1r and C1s to form a functional C1 complex. The occurrence of C1qBP is not limited to certain E. coli strains, but is also found on Staphylococcus aureus, Citrobacter freundii, and Pseudomonas aeruginosa. Also, the binding of 125(I)-labeled C1q to these bacteria is specific because the binding of C1q to these bacteria is inhibitable with isolated soluble C1qBP. These findings provide evidence for the existence of a C1qR-like protein on bacteria that might protect them from complement-mediated damage.

Animals↗
PubMed1984

Diamine-induced dissociation of the first component of human complement, C1.

Lysine has been shown to inhibit spontaneous and antibody-dependent C1 activation. This paper demonstrates that lysine does not prevent autoactivation of purified C1r. 20 mM lysine, 1,2-diaminoethane, 1,3-diaminopropane, 1,4-diaminobutane or 1,5-diaminopentane are able to dissociate C1 into its two entities, C1q and the calcium-dependent C1r2-C1s2 complex. Ig-ovalbumin insoluble complexes bearing C1 are also dissociated by lysine and the above-mentioned diamines used at the same concentration: C1q remains bound to the complexes whereas the C1r2-C1s2 complex is partially solubilized. The effect of lysine or diamines is not due to a competition with calcium for calcium-binding sites, as increasing concentrations of calcium even slightly increase the dissociation due to the amines. The dissociative effect is dependent on the carbon chain length of the diamines, with an optimum for 1,3-diaminopropane. It is also dependent on the relative 'cis-position' of the amino groups in the diamines. Polyamines such as spermine and spermidine are also able to dissociate C1 with even a higher efficiency than lysine and putrescine. Thus, a diamine-induced 'structural inhibition' of C1 is demonstrated, of potential interest for a pharmacological control of complement activation.

Calcium↗
PubMed1986

Biosynthesis of complement C1 inhibitor by Hep G2 cells. Reactivity of different glycosylated forms of the inhibitor with C1s.

The biosynthesis of C1 Inh (C1 inhibitor) was studied in a human hepatoma cell line (Hep G2) by metabolic labelling, immunoprecipitation with anti-(C1 Inh) serum, analysis on SDS/polyacrylamide gel slabs and fluorography. Two forms of C1 Inh are secreted by Hep G2: a minor form of Mr 90,000 and a major form of Mr approximately 100,000. The latter form is also found in small amounts intracellularly in co-existence with an 80,000-Mr form. Accumulation of the 80,000-Mr C1 Inh is favoured when the cells are labelled at 23 degrees C instead of 37 degrees C or when they are treated with monensin. In the presence of tunicamycin, a compound that blocks the formation of N-asparagine-linked oligosaccharide chains, a decrease in Mr of both secreted and intracellular major forms is observed, indicating that secreted and intracellular C1 Inh contain N-linked oligosaccharide units. The 100,000 Mr secreted C1 Inh is sensitive to endoglycosidase F but resistant to endoglycosidase H, and it incorporates [3H]galactose, [3H]glucosamine and [3H]galactosamine, indicating the presence of both N-linked oligosaccharides of the complex type and O-linked oligosaccharides. The intracellular C1 Inh contains N-linked oligosaccharide units of the high-mannose type as demonstrated by endoglycosidase H-sensitivity. The functional activity of C1 Inh during its biosynthesis was tested by studying its reactivity towards C1s. Both secreted and intracellular C1 Inh form covalent-like complexes with purified plasma C1s. The underglycosylated C1 Inh secreted in presence of tunicamycin is still reactive with purified C1s. These results clearly show that sugars are not essential for this inhibitory activity of C1 Inh.

Acetylglucosaminidase↗
PubMed1999

One active C1r subunit is sufficient for the activity of the complement C1 complex: stabilization of C1r in the zymogen form by point mutations.

The binding of C1 (the first component of complement) to immune complexes leads to the autoactivation of C1r through the cleavage of the Arg463-Ile464 bond in the catalytic domain. Spontaneous activation of C1r (and C1) also occurs in the fluid phase, preventing the characterization of the zymogen form of C1r. To overcome this difficulty, the zymogen form of human C1r was stabilized by mutating the Arg in the Arg463-Ile464 bond to Gln. This mutant was designated as mutant QI. Recombinant C1r (wild type (wt) or mutant) was expressed in insect cells using serum-free medium in functionally pure form; therefore, the cell culture supernatant was suitable to reconstruct C1 for the hemolytic assay. Mutant QI was a stable, nonactivable zymogen and showed no hemolytic activity in reconstituted C1. However, this stable zymogen C1r mutant could form an active mixed dimer with the wt C1r, indicating that one active C1r subunit in the C1 complex is sufficient for the full activity of the entire complex. Our experiments also showed that the exchange of C1r monomers between the C1r dimers is completed in less than 16 h even at pH 7 and 4 degrees C. Two other mutants were also constructed by changing Arg463 to Lys, or Ile464 to Phe, and were designated as mutants KI and RF, respectively. Although these substitutions did increase the stability of the proenzyme in the cell culture supernatant, the mutant proteins retained their ability to autoactivate, and both had a wt-like hemolytic activity.

Animals↗
PubMed1982

The inhibition by lysine of the activation of the first component of complement, C1.

Lysine prevented the activation of Cl at low ionic strength or by heat aggregated IgG (aggIgG) measured by the hydrolysis of acetyl tyrosine ethyl ester (ATEe) by Cls. When serum was mixed with aggIgG, complement was activated and consumed. If lysine was present in the serum containing aggIgG, the activation of complement, thus its consumption, was inhibited in a dose-response manner. Cl haemolysis assay which measures the Cl activity to interact with EA (erythrocytes bound with antibody) was used to study the effects of lysine. The results indicate that 50% of Cl haemolysis was inhibited at 3 mM of lysine. Crossed immunoelectrophoresis indicates that Cl in the serum was activated by aggIgG, but Cls thus formed seemed to be soon complexed with Cl inactivator. The presence of lysine prevented the conversion of Cls to Cls completely. It might be possible that lysine binds with the binding sites on Clq, thus preventing the interaction of Clq and C gamma 2.

Complement Activation↗
PubMed1993

C1q, the collagen-like subcomponent of the first component of complement C1, is a membrane protein of guinea pig macrophages.

C1q, a subcomponent of C1--the first component of complement, is synthesized by macrophages (M phi). Immunofluorescence and immunoperoxidase studies first indicated the presence of C1q on the surface of guinea pig (gp) and human peritoneal M phi (Loos, M., Storz, R., Müller, W. and Lemmel, E. M., Immunobiology 1981. 158: 213). In our study different methods for labeling of gp serum and gp M phi C1q were employed. The presence of C1q protein on the surface of gp peritoneal M phi is shown by cell surface labeling with the biotin derivative sulfosuccinimdyl-6-(biotinamido)-hexanoate and subsequent immunoprecipitation. The mechanism by which C1q is attached to the cell membrane was also investigated. Intact cells were treated with acid stripping-buffers or phosphatidylinositol-specific phospholipase C and separated membranes were extracted with a buffer containing 1 M KCl and 3 M urea. Regardless of which method was used, C1q remained attached to the membrane. When surface-labeled cells were cultured, they were found to release the C1q from their surface membrane into the culture medium. Lysates of biosynthetically labeled cells were used to show that, like secreted or serum C1q, cellular M phi C1q binds to immobilized homologous IgG. This implies that the globular regions of the cellular C1q are functionally active. The results reveal that (i) cellular M phi C1q is firmly located in the membrane throughout the biosynthetic pathway, such that it is comparable with an integral membrane protein, (ii) cellular M phi C1q is not reversibly bound to the cell surface via a receptor. We suggest that C1q, as a membrane protein of M phi, serves as an Fc binding factor that also is secreted into the environment.

Animals↗
PubMed1992

Paramyosin inhibits complement C1.

We report here the results of studies showing that inhibition of C is a property of several invertebrate paramyosins. Paramyosins from Taenia solium, Schistosoma mansoni, and the mussel Mytilus edulis bind polymeric collagen and can be isolated from crude extracts of tissues by collagen affinity. These paramyosins inhibit C1 function whether the C1 is isolated or present in C2-deficient serum. Because T. solium paramyosin was the best inhibitor, we concentrated further studies on this molecule. T. solium paramyosin binds purified C1q in solution with a dose/response similar to C1r2S2. Further studies of the C1-paramyosin interaction indicate that: 1) C4 is not activated, 2) C4b2a decay is not affected, and 3) there is no effect on the efficiency of C3-9, as provided in EDTA-chelated guinea pig serum, in lysing SRBC. Thus, paramyosin inhibition is directed at the initiation of the classical pathway. The results suggest that paramyosins of helminthic parasites may have a role as modulators of the host immune response through C inhibition at C1.

Animals↗
PubMed1984

Inhibition of the activation of the first component of complement, C1, by various amino acids or peptides.

The effects of various amino acids (or their analogues) and peptides on the activation or consumption of human complement by erythrocytes bound with hemolysin or heat-aggregated immunoglobulin G (aggIgG) were studied by using the hemolysis of hemolysin-bound erythrocytes, the consumption of complement by aggIgG in the serum, the hydrolysis of acetyl tyrosine ethyl ester by activated Cl (Cls), Cl hemolysis and a newly developed enzyme immunoassay, which directly measures interaction between Clq and aggIgG. Amino acids or peptides which were proposed to comprise Clq binding sites of the C2 region of IgG or their analogues were used. CH50 was inhibited by lysine or arginine to the largest extent, but other amino acids, including tranexamic acid and epsilon-amino caproic acid were not inhibitory up to 60 mM. The consumption of serum complement by aggIgG was prevented by arginine or lysine (about 60% inhibition at 60 mM) and by histidine to a lesser extent. The activation of Cls in the Cl complex by aggIgG precipitated at pH 5.5 was most inhibited by lysine, and to a lesser extent by tranexamic acid, arginine and epsilon-aminocaproic acid, but not glutamic acid or glycine. The results of Cl hemolysis indicated that, of all amino acids soluble at neutral pH, lysine and arginine were most effective in the inhibition of Cl hemolysis. Tranexamic acid and epsilon-aminocaproic acid were less effective, and glycine and norleucine were hardly effective. Among the dipeptides used, those that are composed of aromatic amino acids were very effective in the inhibition of Cl hemolysis.(ABSTRACT TRUNCATED AT 250 WORDS)

Amino Acids↗
PubMed1981

Activation of first component of complement (C1) in guinea pig serum by a polysaccharide is prevented by C1 inhibitor.

A polysaccharide (PS) purified from venom of the ant Pseudomyrmex sp. causes the activation of the classical complement (C) pathway in normal serum, but not in guinea pig serum. To investigate why C was not activated in guinea pig serum, we partially purified guinea pig C1 in the presence of the protease inhibitor p-nitrophenyl, p'-guanidinobenzoate (NPGB). This C1 preparation was activated (mu = 0.15, pH 7.5) by the PS in a dose-dependent reaction after NPGB was eliminated by dilution. The PS decreased the action of the C1 inhibitor for C1 in diluted guinea pig serum, and it also inhibited the activity of highly purified guinea pig C1 inhibitor for C1. There was a direct correlation between the concentration of the guinea pig C1 inhibitor and the loss of ability of the PS to activate C1 in mixtures of constant concentrations of purified guinea pig C1 and purified venom PS, and increasing concentrations of purified guinea pig C1 inhibitor. The activity of the human C1 inhibitor, either in diluted serum or highly purified, was not decreased by the PS. These results show that the PS does not activate guinea pig C1 in serum because its action is blocked by the C1 inhibitor.

Animals↗
PubMed1985

A simple two-step procedure for the preparation of the first component of human complement (C1) in its native form.

Native human C1 was purified from fresh human serum by affinity chromatography on protein A-bound Sepharose in the presence of 4-nitrophenyl-4-guanidinobenzoate hydrochloride (NPGB) taking advantage of the successive binding of IgG to protein A followed by C1 binding to IgG. After elution the C1 preparation contained IgG as a major contaminant as shown by SDS-PAGE. C1 was further purified by gel filtration. The yield of C1 was 12% and less than 4% of this C1 was activated during purification as assessed by a C4 consumption assay.

Chromatography, Affinity↗